Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model.

Benten D, Behrang Y, Unrau L, Weissmann V, Wolters-Eisfeld G, Burdak-Rothkamm S, Stahl FR, Anlauf M, Grabowski P, Möbs M, Dieckhoff J, Sipos B, Fahl M, Eggers C, Perez D, Bockhorn M, Izbicki JR, Lohse AW, Schrader J.

Mol Cancer Res. 2018 Mar;16(3):496-507. doi: 10.1158/1541-7786.MCR-17-0163. Epub 2018 Jan 12.

PMID:
29330294
2.

Prevalence of βIII-tubulin (TUBB3) expression in human normal tissues and cancers.

Person F, Wilczak W, Hube-Magg C, Burdelski C, Möller-Koop C, Simon R, Noriega M, Sauter G, Steurer S, Burdak-Rothkamm S, Jacobsen F.

Tumour Biol. 2017 Oct;39(10):1010428317712166. doi: 10.1177/1010428317712166.

PMID:
29022485
3.

High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer.

Burdelski C, Shihada R, Hinsch A, Angerer A, Göbel C, Friedrich E, Hube-Magg C, Burdak-Rothkamm S, Kluth M, Simon R, Möller-Koop C, Sauter G, Büscheck F, Wittmer C, Clauditz TS, Krech T, Tsourlakis MC, Minner S, Graefen M, Schlomm T, Wilczak W, Jacobsen F.

Prostate. 2017 Nov;77(15):1528-1538. doi: 10.1002/pros.23431. Epub 2017 Sep 19.

PMID:
28929505
4.

Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer.

Jacobsen F, Taskin B, Melling N, Sauer C, Wittmer C, Hube-Magg C, Kluth M, Simon R, Pehrke D, Beyer B, Steuber T, Thederan I, Sauter G, Schlomm T, Wilczak W, Möller K, Weidemann SA, Burdak-Rothkamm S.

BMC Cancer. 2017 Jul 26;17(1):504. doi: 10.1186/s12885-017-3489-9.

5.

Successful mTOR inhibitor therapy for a metastastic neuroendocrine tumour in a patient with a germline TSC2 mutation.

Schrader J, Henes FO, Perez D, Burdak-Rothkamm S, Stein A, Izbicki JR, Lohse AW.

Ann Oncol. 2017 Apr 1;28(4):904-905. doi: 10.1093/annonc/mdx007. No abstract available.

PMID:
28327903
6.

Targeted nanoparticles for tumour radiotherapy enhancement-the long dawn of a golden era?

Gargioni E, Schulz F, Raabe A, Burdak-Rothkamm S, Rieckmann T, Rothkamm K.

Ann Transl Med. 2016 Dec;4(24):523. doi: 10.21037/atm.2016.12.46.

7.

FGFR1 Amplification Is Often Homogeneous and Strongly Linked to the Squamous Cell Carcinoma Subtype in Esophageal Carcinoma.

von Loga K, Kohlhaussen J, Burkhardt L, Simon R, Steurer S, Burdak-Rothkamm S, Jacobsen F, Sauter G, Krech T.

PLoS One. 2015 Nov 10;10(11):e0141867. doi: 10.1371/journal.pone.0141867. eCollection 2015.

8.

DNA damage foci: Meaning and significance.

Rothkamm K, Barnard S, Moquet J, Ellender M, Rana Z, Burdak-Rothkamm S.

Environ Mol Mutagen. 2015 Jul;56(6):491-504. doi: 10.1002/em.21944. Epub 2015 Mar 12. Review.

PMID:
25773265
9.

BRCA1, FANCD2 and Chk1 are potential molecular targets for the modulation of a radiation-induced DNA damage response in bystander cells.

Burdak-Rothkamm S, Rothkamm K, McClelland K, Al Rashid ST, Prise KM.

Cancer Lett. 2015 Jan 28;356(2 Pt B):454-61. doi: 10.1016/j.canlet.2014.09.043. Epub 2014 Oct 7.

10.

Radioprotection of targeted and bystander cells by methylproamine.

Burdak-Rothkamm S, Smith A, Lobachevsky P, Martin R, Prise KM.

Strahlenther Onkol. 2015 Mar;191(3):248-55. doi: 10.1007/s00066-014-0751-9. Epub 2014 Sep 23.

11.

Ionizing radiation-induced DNA strand breaks and γ-H2AXγ-H2AX foci in cells exposed to nitric oxide.

Rothkamm K, Burdak-Rothkamm S.

Methods Mol Biol. 2011;704:17-25. doi: 10.1007/978-1-61737-964-2_2.

PMID:
21161626
12.

Cohesin promotes the repair of ionizing radiation-induced DNA double-strand breaks in replicated chromatin.

Bauerschmidt C, Arrichiello C, Burdak-Rothkamm S, Woodcock M, Hill MA, Stevens DL, Rothkamm K.

Nucleic Acids Res. 2010 Jan;38(2):477-87. doi: 10.1093/nar/gkp976. Epub 2009 Nov 11.

13.

New molecular targets in radiotherapy: DNA damage signalling and repair in targeted and non-targeted cells.

Burdak-Rothkamm S, Prise KM.

Eur J Pharmacol. 2009 Dec 25;625(1-3):151-5. doi: 10.1016/j.ejphar.2009.09.068. Epub 2009 Oct 14. Review.

14.

DNA and chromosomal damage in response to intermittent extremely low-frequency magnetic fields.

Burdak-Rothkamm S, Rothkamm K, Folkard M, Patel G, Hone P, Lloyd D, Ainsbury L, Prise KM.

Mutat Res. 2009 Jan 31;672(2):82-9. doi: 10.1016/j.mrgentox.2008.10.016. Epub 2008 Nov 13.

PMID:
19049903
15.

Oral polio vaccination leads to oligoclonal expansion of TCRBV16+ and TCRBV13+ T cells in the colon of rhesus macaques.

Hörer S, Burdak-Rothkamm S, Allers K, Schneider T, Duchmann R.

Exp Mol Pathol. 2008 Dec;85(3):189-95. doi: 10.1016/j.yexmp.2008.08.001. Epub 2008 Aug 15.

PMID:
18775423
16.

ATM acts downstream of ATR in the DNA damage response signaling of bystander cells.

Burdak-Rothkamm S, Rothkamm K, Prise KM.

Cancer Res. 2008 Sep 1;68(17):7059-65. doi: 10.1158/0008-5472.CAN-08-0545.

17.

Cytoplasmic irradiation induces mitochondrial-dependent 53BP1 protein relocalization in irradiated and bystander cells.

Tartier L, Gilchrist S, Burdak-Rothkamm S, Folkard M, Prise KM.

Cancer Res. 2007 Jun 15;67(12):5872-9.

18.

ATR-dependent radiation-induced gamma H2AX foci in bystander primary human astrocytes and glioma cells.

Burdak-Rothkamm S, Short SC, Folkard M, Rothkamm K, Prise KM.

Oncogene. 2007 Feb 15;26(7):993-1002. Epub 2006 Aug 7.

PMID:
16909103
19.

Radiosensitivity of tumor cell lines after pretreatment with the EGFR tyrosine kinase inhibitor ZD1839 (Iressa).

Burdak-Rothkamm S, Rübe CE, Nguyen TP, Ludwig D, Feldmann K, Wiegel T, Rübe C.

Strahlenther Onkol. 2005 Mar;181(3):197-204.

PMID:
15756525
20.

Irradiation induces a biphasic expression of pro-inflammatory cytokines in the lung.

Rübe CE, Wilfert F, Palm J, König J, Burdak-Rothkamm S, Liu L, Schuck A, Willich N, Rübe C.

Strahlenther Onkol. 2004 Jul;180(7):442-8.

PMID:
15241532

Supplemental Content

Loading ...
Support Center